Phase 2/3Active, not recruitingNCT03899402
Triple therapy in T1D
Phase 2/3 trial of combination adjunct therapy in type 1 diabetes, included as part of the metabolic-adjunct long tail.
Primary endpoints
- Change in HbA1c following dapagliflozin
Results so far
No results posted yet.